Sonnet BioTherapeutics Quote - SONN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

Bid

Ask

Volume

0.00 Day's Range 0.00

0.8705 52 Week Range 12.10

Market Cap

2.895M

Previous Close

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

35,361

Shares Outstanding

3,112,401

Dividend Yield

PE Ratio

-0.15

Earnings Per Share (EPS)

-6.05

Revenue

148k

Net Profit

-18.83M

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Show more

Sector

Pharmaceutical Preparations

Industry

Management Consulting Svcs

Website

www.sonnetbio.com

Headquarters

Wilmington, Delaware, USA

Founded

2020

Sonnet BioTherapeutics Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SONN. The last closing price for Sonnet BioTherapeutics was -. Over the last year, Sonnet BioTherapeutics shares have traded in a share price range of US$ 0.8705 to US$ 12.10.

Sonnet BioTherapeutics currently has 3,112,401 shares outstanding. The market capitalization of Sonnet BioTherapeutics is US$2.89 million. Sonnet BioTherapeutics has a price to earnings ratio (PE ratio) of -0.15.

Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds

PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic...

Form 8-K - Current report

Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain

Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with...

Period †	Open	High	Low	Avg. Daily Vol	VWAP
1	1.03	1.04	0.8705	95475	0.94850732	CS
4	1.64	2	0.8705	63023	1.17255772	CS
12	1.97	2.1	0.8705	35361	1.41777471	CS
26	1.56	2.3399	0.8705	71327	1.8162774	CS
52	11	12.1	0.8705	388252	7.40950292	CS
156	477.4	637.56	0.8705	2838311	137.91630772	CS
260	1915.76	4989.6	0.8705	2507929	329.61978737	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DNDelta 9 Cannabis Inc	$ 0.015 (50.00%)	1.1M
BRMIBoat Rocker Media Inc	$ 1.02 (29.11%)	1.84M
TSATTelesat Corporation	$ 12.50 (17.26%)	3.24k
QECQuesterre Energy Corporation	$ 0.25 (16.28%)	24.6k
GEOGeodrill Limited	$ 2.30 (15.58%)	47.28k
NCPNickel Creek Platinum Corp	$ 0.01 (-33.33%)	1.07k
LPENLoop Energy Inc	$ 0.025 (-28.57%)	73.62k
ASNDAscendant Resources Inc	$ 0.035 (-22.22%)	1,000
FLNTFlint Corporation	$ 0.025 (-16.67%)	16.5k
BNGBengal Energy Ltd	$ 0.03 (-14.29%)	85k
TRPTC Energy Corporation	$ 51.87 (-1.76%)	34.35M
BNSBank of Nova Scotia	$ 62.58 (0.29%)	18.9M
POWPower Corp of Canada	$ 38.02 (-1.66%)	13.19M
TDToronto Dominion Bank	$ 75.20 (0.09%)	9.87M
MFCManulife Financial Corporation	$ 36.44 (0.41%)	6.48M